Prandin (repaglinide), a new oral hypoglycemic for type 2 diabetes

May 1998

You'll soon see Prandin (repaglinide), a new oral hypoglycemicfor type 2 diabetes...co-marketed by Novo Nordisk and Schering.

It's approved for monotherapy...and for use with metformin(Glucophage). It's also being tested with troglitazone (Rezulin).

Prandin is the first drug in a new class...the meglitinides.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

Cutting-edge advice about new medications and how they fit into practice
Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote